INOVIQ FCF per Share

What does INOVIQ do? INOVIQ Ltd. provides medical services through its two market products, the hTERT ICC test and EXO-NET Pan-Exosome. The hTERT ICC test is an immunocytochemistry assay registered for detecting human telomerase reverse transcriptase in cytopathology samples, used as an adjunct to urine cytology to help resolve indeterminate results and identify patients at higher risk of bladder cancer. EXO-NET Pan-Exosome is a research use only tool for isolating exosomes from body fluids like plasma, urine, and saliva. The company's cancer diagnostic pipeline includes blood tests under development for early detection and monitoring of ovarian, breast, prostate, and other cancers. The hTERT ICC test is purchased by healthcare providers for diagnostic use in resolving ambiguous cytology results, particularly in bladder cancer risk assessment. EXO-NET Pan-Exosome is sold to research institutions and laboratories for exosome isolation in scientific studies. The blood tests in development target medical professionals involved in cancer diagnostics and monitoring, aiming to support earlier detection of multiple cancer types. INOVIQ Ltd. generates revenue primarily through the sale of its diagnostic products to medical facilities and research entities. The hTERT test serves clinical settings for bladder cancer risk identification, while EXO-NET supports research applications in exosome analysis. The company's pipeline products are positioned for future commercialization in the cancer diagnostics market. INOVIQ is one of the most popular companies on Eulerpool.